Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

261. Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer. Full Text available with Trip Pro

Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer. To investigate the effects of oral zinc supplementation on fatigue intensity and quality of life of patients during chemotherapy for colorectal cancer.A prospective, randomized, double-blinded, placebo-controlled study was conducted with 24 patients on chemotherapy for colorectal adenocarcinoma in a tertiary care public hospital. The study patients received zinc capsules 35mg (Zinc Group, n=10 (...) and fatigue questionnaires were similar between the groups during the chemotherapy cycles. The Placebo Group presented worsening of quality of life and increased fatigue between the first and fourth cycles of chemotherapy, but there were no changes in the scores of quality of life or fatigue in the Zinc Group.Zinc supplementation prevented fatigue and maintained quality of life of patients with colorectal cancer on chemotherapy.Investigar os efeitos da suplementação oral de zinco sobre a intensidade da

2017 Einstein (Sao Paulo, Brazil) Controlled trial quality: uncertain

262. Heterogeneity of colon cancer: from bench to bedside Full Text available with Trip Pro

Heterogeneity of colon cancer: from bench to bedside The large bowel shows biomolecular, anatomical and bacterial changes that proceed from the proximal to the distal tract. These changes account for the different behaviour of colon cancers arising from the diverse sides of the colon-rectum as well as for the sensitivity to the therapy, including immunotherapy. The gut microbiota plays an important role in the modulation of the immune response and differs between the right colon cancer (...) and the left colorectal cancer. The qualitative and quantitative difference of the commensal bacteria between the right side and the left side induces epigenetic changes in the intestinal epithelial cells as well as in the resident immune population. The second player in the pathological homeostasis of colorectal cancer is the differences of the genetic features of cancer cells and the different effects that microsatellite instability, chromosomal instability and the CpG island methylator phenotype induce

2017 ESMO open

263. Challenges in Decision Making in Elderly Patients with Gastrointestinal Malignancies Full Text available with Trip Pro

Challenges in Decision Making in Elderly Patients with Gastrointestinal Malignancies 29034257 2018 08 01 2297-4725 33 4 2017 Aug Visceral medicine Visc Med Challenges in Decision Making in Elderly Patients with Gastrointestinal Malignancies. 281-283 10.1159/000478806 Wedding Ulrich U Department of Internal Medicine II (Haematology, Oncology, Palliative Care), University Hospital Jena, Jena, Germany. Audisio Riccardo A RA Department of Surgery, University of Liverpool, St Helens Teaching

2017 Visceral medicine

264. Challenges in Decision Making in Elderly Patients with Gastrointestinal Malignancies Full Text available with Trip Pro

Challenges in Decision Making in Elderly Patients with Gastrointestinal Malignancies 29034251 2019 01 16 2297-4725 33 4 2017 Aug Visceral medicine Visc Med Challenges in Decision Making in Elderly Patients with Gastrointestinal Malignancies. 244 10.1159/000480254 Wedding Ulrich U Department of Internal Medicine II (Haematology, Oncology, Palliative Care), University Hospital Jena, Jena, Germany. Richter Konrad Klaus KK Department of Surgery, Southland Hospital, Invercargill, New Zealand

2017 Visceral medicine

265. Perioperative Management of Elderly Patients with Gastrointestinal Malignancies: The Contribution of Anesthesia Full Text available with Trip Pro

Perioperative Management of Elderly Patients with Gastrointestinal Malignancies: The Contribution of Anesthesia Elderly patients suffering from gastrointestinal malignancies are particularly prone to perioperative complications. Elderly patients often present with reduced physiological reserves, and comorbidities can limit treatment options and promote complications. Surgeons and anesthesiologists must be aware of strategies required to deal with this vulnerable subgroup.We provide a brief (...) review of current and emerging perioperative strategies for the treatment of elderly patients with gastrointestinal malignancies and frequent comorbidities.Especially in combination with advanced age, the effects of malignancies can be devastating, bringing new health challenges, exacerbating preexisting conditions, and exerting severe psychological strain. An interdisciplinary assessment and process planning provide an ideal setting to identify and prevent potential complications, especially

2017 Visceral medicine

266. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study Full Text available with Trip Pro

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic spindle poisons on BRAF-mutated and BRAF-like CRC models. We designed a phase II trial to test the activity of vinorelbine in patients with BRAF V600E mutated metastatic CRC (mCRC).Patients progressed to or not deemed (...) eligible for standard treatments received oral (60 mg/sqm) or intravenous (25 mg/sqm) vinorelbine, on days 1 and 8 every 21 days. Primary endpoint was objective response rate (ORR).Twenty patients were enrolled; 75% of them were highly pretreated. No responses were observed (0%); only one patient had a confirmed disease stabilisation (5%). Median progression-free survival was 1 month (95% CI 0.8 to 1.8), median overall survival was 2.1 months (95% CI 1.6 to 3.7). No serious adverse events were

2017 ESMO open

267. Risk Factors for Adverse Outcome for Elderly Patients undergoing Curative Oncological Resection for Gastrointestinal Malignancies Full Text available with Trip Pro

Risk Factors for Adverse Outcome for Elderly Patients undergoing Curative Oncological Resection for Gastrointestinal Malignancies The incidence of gastrointestinal cancer increases with age, with approximately 20% of these cases in people over 80 years of age. Due to pre-existing comorbidities, this onco-geriatric population often presents diagnostic and therapeutic challenges.A systematic review of articles on PubMed was performed to determine the predictive ability of screening tools (...) and their components regarding the occurrence of adverse outcomes in elderly onco-surgical patients with gastrointestinal malignancies.Surgical procedures in this patient cohort, particularly complex resections, may result in increased morbidity and mortality. The decision to treat an elderly patient with curative intent requires sound clinical judgment based on knowledge, consideration of objective parameters, and experience. These patients could potentially be optimized for surgery with the improvement

2017 Visceral medicine

268. Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014 Full Text available with Trip Pro

Society, Atlanta, Georgia. Jemal Ahmedin A Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. eng Letter United States JAMA 7501160 0098-7484 AIM IM Adult African Americans Age Distribution Colorectal Neoplasms ethnology mortality European Continental Ancestry Group Female Humans Male Middle Aged Mortality trends United States epidemiology Young Adult 2017 8 9 6 0 2017 8 9 6 0 2017 9 21 6 0 ppublish 28787497 2647859 10.1001/jama.2017.7630 PMC5817468 Cancer (...) Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014 28787497 2017 09 20 2018 11 13 1538-3598 318 6 2017 08 08 JAMA JAMA Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014. 572-574 10.1001/jama.2017.7630 Siegel Rebecca L RL Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. Miller Kimberly D KD Surveillance and Health Services Research Program, American Cancer

2017 JAMA

269. Age and Outcome in Gastrointestinal Cancers: A Population-Based Evaluation of Oesophageal, Gastric and Colorectal Cancer Full Text available with Trip Pro

Age and Outcome in Gastrointestinal Cancers: A Population-Based Evaluation of Oesophageal, Gastric and Colorectal Cancer With demographic changes and partial representativeness of randomized studies the question arises which results are achieved in the treatment of the elderly. The objective was to analyse population-based data on gastrointestinal cancers in terms of age.Analyses included data of the Munich Cancer Registry, i.e. 4,014, 10,127 and 42,809 invasive oesophageal, gastric (...) and colorectal cancer patients, respectively, which were diagnosed between 1998 and 2014. Tumour characteristics and outcome were analysed by age groups and therapy. Overall survival was analysed using the Kaplan-Meier method, and relative survival was computed as estimation for cancer-specific survival. Additionally, conditional survival of patients surviving at least 6 or 12 months was analysed by age.21, 44 and 38% of oesophageal, gastric and colorectal cancer patients, respectively, were aged >75 years

2017 Visceral medicine

270. An Unusual Diagnosis in a Patient with Suspected Colorectal Cancer Full Text available with Trip Pro

Journal Article 2017 08 04 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Colonic lipoma Colonoscopy Colorectal cancer 2017 03 14 2017 05 18 2017 12 20 6 0 2017 12 20 6 0 2017 12 20 6 1 ppublish 29255776 10.1159/000478942 pjg-0024-0308 PMC5731160 Gastrointest Endosc. 2000 Apr;51(4 Pt 1):495-6 10744833 Gastrointest Endosc. 2003 Sep;58(3):468-70 14528235 World J Gastroenterol. 2007 May 7;13(17):2510-3 17552037 (...) An Unusual Diagnosis in a Patient with Suspected Colorectal Cancer 29255776 2018 11 13 2341-4545 24 6 2017 Nov GE Portuguese journal of gastroenterology GE Port J Gastroenterol An Unusual Diagnosis in a Patient with Suspected Colorectal Cancer. 308-310 10.1159/000478942 Carmo Joana J Department of Gastroenterology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. Marques Susana S Department of Gastroenterology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa

2017 GE Portuguese journal of gastroenterology

271. Integration of Geriatric Assessment in the Care of Patients with Gastrointestinal Malignancies Full Text available with Trip Pro

Integration of Geriatric Assessment in the Care of Patients with Gastrointestinal Malignancies The majority of patients with gastrointestinal (GI) malignancies are older. Recently, it has become evident that elements from a geriatric assessment (GA) are powerful predictors of outcomes such as postoperative morbidity and mortality, length of stay, type of treatment received, and survival across several GI tumor types in older adults. A GA is a systematic evaluation of functional status (...) , comorbidities, polypharmacy, cognition, nutritional status, emotional status, and social support.A PubMed search was performed in order to identify clinical studies investigating the association between GA and outcomes in patients with GI malignancies.A total of 31 studies were included in this review. For colorectal cancer, the evidence linking GA variables and frailty to negative outcomes is substantial and consistent. The data regarding other GI malignancies is more limited, but generally shows the same

2017 Visceral medicine

272. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals (...) patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment 2017; 21(33) Authors' objectives To assess the effectiveness of FITs [OC-Sensor (Eiken Chemical Co./MAST Diagnostics, Tokyo, Japan), HM-JACKarc (Kyowa Medex/Alpha Laboratories Ltd, Tokyo, Japan), FOB Gold (Sentinel/Sysmex, Sentinel Diagnostics, Milan, Italy), RIDASCREEN Hb or RIDASCREEN Hb/Hp complex (R-Biopharm, Darmstadt

2017 Health Technology Assessment (HTA) Database.

273. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care

lower gastrointestinal symptoms can suggest colorectal cancer, including rectal bleeding, a change in bowel habits, weight loss, anaemia, abdominal pain, and blood in stools (faeces). Sometimes, blood in stools is not visible (faecal occult blood) so tests are used to detect its presence. These faecal occult blood tests can be used in primary care to assess people who are at a low risk of colorectal cancer and help determine whether they should be referred for further investigations where they do (...) a suspected cancer referral to establish a diagnosis. Faecal occult blood can be caused by conditions other than colorectal cancer, such as colorectal polyps and inflammatory bowel disease, so further assessment with a colonoscopy is needed to diagnose colorectal cancer; a positive faecal occult blood test was not intended be used alone. 2.9 Colonoscopy is considered to be the gold standard for diagnosing colorectal cancer because the entire colon can usually be seen and biopsies can be taken to assess

2017 National Institute for Health and Clinical Excellence - Diagnostics Guidance

274. Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54

Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54 1 Translation of addendum A16-77 Trifluridin/Tipiracil (Kolorektalkarzinom) – Addendum zum Auftrag A16-54 (Version 1.0; Status: 13 January 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 13 January 2017 1.0 Commission: A16-77 Version: Status: IQWiG Reports – Commission (...) No. A16-77 Trifluridine/tipiracil (colorectal cancer) – Addendum to Commission A16-54 1 Addendum A16-77 Version 1.0 Trifluridine/tipiracil – Addendum to Commission A16-54 13 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Trifluridine/tipiracil (colorectal cancer) – Addendum to Commission A16-54 Commissioning agency: Federal Joint Committee Commission awarded on: 22 December 2016

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

275. Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V

and in the placebo + BSC arm. Death was recorded as the reason of study discontinuation in nearly all cases; an additional 3 patients were lost to follow-up in each of both study arms. One additional patient withdrew consent in the trifluridine/tipiracil + BSC arm. Although according to the approval, treatment with trifluridine/tipiracil, in principle, is an option for all tumour types of colorectal cancer [5], the RECOURSE study only included patients with adenocarcinoma. With more than 95%, this tumour type (...) of the company, which claimed proof of an added benefit for the total population in the category of serious or severe symptoms for the outcomes Extract of dossier assessment A16-54 Version 1.0 Trifluridine/tipiracil (colorectal cancer) 11 November 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - 24 - “progression-free survival (PFS)”, tumour assessment (disease control rate), time to treatment failure and time to reaching an ECOG PS = 2. Health-related quality of life Health-related quality

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

276. Left Adrenal Tumor Disappeared Outside a Field of Vision During Laparoscopic Surgery: The True Identity Was Gastrointestinal Stromal Tumor Full Text available with Trip Pro

Left Adrenal Tumor Disappeared Outside a Field of Vision During Laparoscopic Surgery: The True Identity Was Gastrointestinal Stromal Tumor Background: We report a case of gastrointestinal stromal tumor (GIST) mimicking a left adrenal tumor. Case Presentation: A 62-year-old female was referred to our hospital for the treatment of left adrenal tumor of 2.8 × 2.3 cm incidentally found during her annual checkup. The preoperative diagnosis based on upper gastroscopy and imaging complete examinations (...) was nonfunctional left adrenal tumor possessing malignant potential. Transperitoneal laparoscopic left adrenalectomy was performed. However, the tumor was not found in the excised adrenal gland that had been completely removed during surgery. Repeat computed tomography revealed the presence of the same tumor. Finally, reoperation led us to the true diagnosis of GIST. Conclusion: Many urologists are not familiar with GIST. It is necessary to take GIST into consideration when left adrenal tumor close

2017 Journal of endourology case reports

277. Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test Full Text available with Trip Pro

TR Division of Research, Kaiser Permanente Northern California, Oakland. eng U54 CA163262 CA NCI NIH HHS United States Letter Comment United States JAMA 7501160 0098-7484 AIM IM JAMA. 2017 Apr 25;317(16):1627-1628 28444260 JAMA. 2017 Aug 1;318(5):483-484 28763547 Colonoscopy Colorectal Neoplasms Early Detection of Cancer Humans Mass Screening Occult Blood 2017 8 2 6 0 2017 8 2 6 0 2017 9 8 6 0 ppublish 28763543 2646711 10.1001/jama.2017.9312 PMC6197858 NIHMS988941 J Comp Eff Res. 2015 Nov;4(6 (...) Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test 28763543 2017 09 07 2018 11 13 1538-3598 318 5 2017 08 01 JAMA JAMA Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test. 483 10.1001/jama.2017.9312 Doubeni Chyke A CA Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia. Corley Douglas A DA Division of Research, Kaiser Permanente Northern California, Oakland. Levin Theodore R

2017 JAMA

278. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment Full Text available with Trip Pro

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment To investigate the potential predictors of response to regorafenib, in chemorefractory metastatic colorectal cancer (mCRC) patients with long-term efficacy from regorafenib treatment.Retrospective, single institution analysis of patients with chemorefractory mCRC treated with regorafenib, in clinical practice setting. 123 patients were treated (...) and stratified into two groups according to number of cycles received (<7 and ≥7). Overall survival (OS), progression-free survival (PFS) and safety were evaluated. 20 tumour samples (10 poor and 10 long responders) were analysed with the OncoMine Comprehensive Assay for 143 genes.A good Eastern Cooperative Oncology Group performance status, a lung limited metastatic disease and a long history of metastatic disease were significantly associated with better OS and PFS from treatment with regorafenib

2017 ESMO open

279. Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer Full Text available with Trip Pro

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer 29303156 2019 01 30 2059-7029 2 3 2017 ESMO open ESMO Open Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. e000205 10.1136/esmoopen-2017-000205 Prager Gerald G Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University Vienna, Vienna, Austria. Argilés Guillem G Vall d'Hebrón Institut of Oncology (VHIO), Vall d'Hebrón University

2017 ESMO open

280. Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia Full Text available with Trip Pro

for patients with advanced pancreatic cancer.Twenty-nine chemotherapy-naive patients with locally advanced or metastatic pancreatic carcinoma with malignant ascites were treated with intraperitoneal cisplatin 30 mg/m2 and gemcitabine 800 to 1,000 mg/m2 intravenously on days 1, 8, and 15 every 28 days until tumor progression. Patients also received regional hyperthermia treatment (41 to 42°C) on the upper abdomen two times per week from days 1 to 21.In all, 83 cycles of chemotherapy were administered (...) Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia Hyperthermia is a mechanistically plausible partner with chemotherapy, although many of the underlying molecular mechanisms of this combination treatment are not yet properly understood. Preclinical studies suggest that there is potential synergy with gemcitabine and that provides the basis for retrospective analysis of a clinical series combining these treatment modalities

2017 Journal of global oncology